FR2525603A1 - Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique - Google Patents

Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique Download PDF

Info

Publication number
FR2525603A1
FR2525603A1 FR8207203A FR8207203A FR2525603A1 FR 2525603 A1 FR2525603 A1 FR 2525603A1 FR 8207203 A FR8207203 A FR 8207203A FR 8207203 A FR8207203 A FR 8207203A FR 2525603 A1 FR2525603 A1 FR 2525603A1
Authority
FR
France
Prior art keywords
spiro
formula
salt
dione
isoquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8207203A
Other languages
English (en)
French (fr)
Other versions
FR2525603B1 (de
Inventor
Charles Malen
Jean-Louis Peglion
Jacques Duhault
Michele Boulanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Priority to FR8207203A priority Critical patent/FR2525603A1/fr
Priority to AT0125383A priority patent/ATA125383A/de
Priority to DD83250187A priority patent/DD209833A5/de
Priority to LU84770A priority patent/LU84770A1/fr
Priority to IL68497A priority patent/IL68497A0/xx
Priority to GR71214A priority patent/GR78481B/el
Priority to BE0/210633A priority patent/BE896572A/fr
Priority to AU13953/83A priority patent/AU1395383A/en
Priority to PT76595A priority patent/PT76595B/pt
Priority to KR1019830001753A priority patent/KR840004428A/ko
Priority to SE8302347A priority patent/SE8302347L/xx
Priority to ZA832927A priority patent/ZA832927B/xx
Priority to IT48155/83A priority patent/IT1167123B/it
Priority to NO831473A priority patent/NO831473L/no
Priority to NL8301476A priority patent/NL8301476A/nl
Priority to DK183583A priority patent/DK183583A/da
Priority to JP58073687A priority patent/JPS5910584A/ja
Priority to OA57984A priority patent/OA07412A/xx
Priority to MA20003A priority patent/MA19783A1/fr
Priority to GB08311508A priority patent/GB2133401B/en
Priority to DE19833315106 priority patent/DE3315106A1/de
Priority to ES521895A priority patent/ES8405796A1/es
Publication of FR2525603A1 publication Critical patent/FR2525603A1/fr
Application granted granted Critical
Publication of FR2525603B1 publication Critical patent/FR2525603B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR8207203A 1982-04-27 1982-04-27 Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique Granted FR2525603A1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
FR8207203A FR2525603A1 (fr) 1982-04-27 1982-04-27 Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique
AT0125383A ATA125383A (de) 1982-04-27 1983-04-08 Verfahren zur herstellung von neuen benzoazacycloalkyl-spiro-imidazolidinen
LU84770A LU84770A1 (fr) 1982-04-27 1983-04-25 Benzoazacycloalkyl-spiro-imidazolidines,leur preparation et leur application en therapeutique
DD83250187A DD209833A5 (de) 1982-04-27 1983-04-25 Verfahren zur herstellung von benzoazacycloalkyl-spiro-imidazolidinen
DK183583A DK183583A (da) 1982-04-27 1983-04-26 Fremgangsmaade til fremstilling af benzoazacycloalkyl-spiro-imidazolidiner
BE0/210633A BE896572A (fr) 1982-04-27 1983-04-26 Benzoazacycloalkyl-spiro-imidazolidines leur preparation et leur application en therapeutique
AU13953/83A AU1395383A (en) 1982-04-27 1983-04-26 Benzoazacycloalkyl-spiro-imidazolidines
PT76595A PT76595B (fr) 1982-04-27 1983-04-26 Procede de preparation de benzoazacycloalkyl-spiro-imidazolidines
KR1019830001753A KR840004428A (ko) 1982-04-27 1983-04-26 벤조 아자시클로 알킬-스피로-이미다졸리딘의 제조방법
SE8302347A SE8302347L (sv) 1982-04-27 1983-04-26 Bensoazacykloalkyl-spiro-imidazolidiner, framstellning derav och farmaceutiska kompositioner innehallande dem
IL68497A IL68497A0 (en) 1982-04-27 1983-04-26 Benzoazacycloalkyl-spiro-imidazolidines,their preparation and pharmaceutical compositions containing them
IT48155/83A IT1167123B (it) 1982-04-27 1983-04-26 Benzoazacicloalchilspiro-imidazolidine,procedimento per prepararle e composizioni farmaceutiche che le contengono
NO831473A NO831473L (no) 1982-04-27 1983-04-26 Fremgangsmaate ved fremstilling av benzoazacykloalkyl-spiro-imidazolidiner
NL8301476A NL8301476A (nl) 1982-04-27 1983-04-26 Benzoazacycloalkylspiroimidazolidines, hun bereiding en farmaceutische samenstellingen welke deze bevatten.
GR71214A GR78481B (de) 1982-04-27 1983-04-26
JP58073687A JPS5910584A (ja) 1982-04-27 1983-04-26 イミダゾリジン誘導体
ZA832927A ZA832927B (en) 1982-04-27 1983-04-26 Benzoazacycloalkyl-spiro-imidazolidines,their preparation and compositions containing them
OA57984A OA07412A (fr) 1982-04-27 1983-04-27 Benzoazacycloalhyl-spiro-imidazolidines leur préparation et leur application en thérapeutique.
MA20003A MA19783A1 (fr) 1982-04-27 1983-04-27 Procede de preparation de benzoazacycloalkyl-spiro-imidazolidines.
GB08311508A GB2133401B (en) 1982-04-27 1983-04-27 Benzoazacycloalkyl-spiro-imidazolidines
DE19833315106 DE3315106A1 (de) 1982-04-27 1983-04-27 Benzoazacycloalkyl-spiro-imidazolidine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
ES521895A ES8405796A1 (es) 1982-04-27 1983-04-27 Procedimiento de preparacion de benzoazacicloalquil-espiroimidazolidina, asi como de sus sales obtenidas con bases minerales u organicas farmaceuticamente aceptables.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8207203A FR2525603A1 (fr) 1982-04-27 1982-04-27 Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2525603A1 true FR2525603A1 (fr) 1983-10-28
FR2525603B1 FR2525603B1 (de) 1984-09-14

Family

ID=9273425

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8207203A Granted FR2525603A1 (fr) 1982-04-27 1982-04-27 Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique

Country Status (22)

Country Link
JP (1) JPS5910584A (de)
KR (1) KR840004428A (de)
AT (1) ATA125383A (de)
AU (1) AU1395383A (de)
BE (1) BE896572A (de)
DD (1) DD209833A5 (de)
DE (1) DE3315106A1 (de)
DK (1) DK183583A (de)
ES (1) ES8405796A1 (de)
FR (1) FR2525603A1 (de)
GB (1) GB2133401B (de)
GR (1) GR78481B (de)
IL (1) IL68497A0 (de)
IT (1) IT1167123B (de)
LU (1) LU84770A1 (de)
MA (1) MA19783A1 (de)
NL (1) NL8301476A (de)
NO (1) NO831473L (de)
OA (1) OA07412A (de)
PT (1) PT76595B (de)
SE (1) SE8302347L (de)
ZA (1) ZA832927B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
AU617541B2 (en) * 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
EP1636191A2 (de) 2003-06-17 2006-03-22 Arena Pharmaceuticals, Inc. Für die behandlung von mit dem 5ht2c rezeptor assoziierten krankheiten geeignete benzazepinderivative
CN1805938B (zh) 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
NZ555981A (en) 2004-12-21 2011-01-28 Arena Pharm Inc Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
EP1833473B1 (de) 2004-12-23 2009-09-09 Arena Pharmaceuticals, Inc. 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
CA2646044A1 (en) 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
CA2670285A1 (en) 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
WO2009111004A1 (en) 2008-03-04 2009-09-11 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
CN102648170A (zh) 2009-06-18 2012-08-22 艾尼纳制药公司 制备5-ht2c受体激动剂的方法
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
MX2013002418A (es) 2010-09-01 2013-08-01 Arena Pharm Inc Administracion de lorcaserina a individuos con daño renal.
SG188361A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
CN103189053A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 用于体重控制的5-ht2c激动剂的调节释放剂型
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
BR112015007779A2 (pt) 2012-10-09 2017-07-04 Arena Pharm Inc célula de fluxo de permeabilidade e sistema de condutância hidráulica

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021704A1 (de) * 1979-06-13 1981-01-07 Pfizer Inc. Spiro-Hydantoin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209630A (en) * 1976-10-18 1980-06-24 Pfizer Inc. Hydantoin derivatives as therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0021704A1 (de) * 1979-06-13 1981-01-07 Pfizer Inc. Spiro-Hydantoin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
FR2525603B1 (de) 1984-09-14
JPS5910584A (ja) 1984-01-20
PT76595B (fr) 1986-01-21
BE896572A (fr) 1983-10-26
MA19783A1 (fr) 1983-12-31
KR840004428A (ko) 1984-10-15
PT76595A (fr) 1983-05-01
SE8302347D0 (sv) 1983-04-26
IT8348155A0 (it) 1983-04-26
OA07412A (fr) 1984-11-30
IL68497A0 (en) 1983-07-31
SE8302347L (sv) 1983-10-28
GB8311508D0 (en) 1983-06-02
DK183583A (da) 1983-10-28
NO831473L (no) 1983-10-28
AU1395383A (en) 1983-11-03
NL8301476A (nl) 1983-11-16
DD209833A5 (de) 1984-05-23
IT1167123B (it) 1987-05-13
ATA125383A (de) 1986-05-15
GR78481B (de) 1984-09-27
GB2133401B (en) 1985-10-23
LU84770A1 (fr) 1984-11-28
DE3315106A1 (de) 1983-11-03
GB2133401A (en) 1984-07-25
ES521895A0 (es) 1984-06-16
ES8405796A1 (es) 1984-06-16
ZA832927B (en) 1984-06-27
DK183583D0 (da) 1983-04-26

Similar Documents

Publication Publication Date Title
FR2525603A1 (fr) Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique
US4200642A (en) Spiro-oxazolidindiones
EP0202164B1 (de) (Benzoyl-4-piperidino)-2-phenyl-1-alkanolderivate, ihre Herstellung und ihre Verwendung als Heilmittel
EP0281459A1 (de) Rechtsdrehendes Enantiomer von alpha-(4,5,6,7-Tetrahydrothieno[3,2-c]pyrid-5-yl)(2-chlorphenyl)methylacetat, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen
EP0051023B1 (de) Derivate der Benzoyl- und alpha-Hydroxybenzyl-phenyl-osid-Familie, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
WO1985004652A1 (fr) Derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications
CA2176668C (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
EP0370901A1 (de) Zentralnervensystem wirksame Chromanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
US4283539A (en) Isoquinoline acetic acids
FR2620121A1 (fr) ((pyrimidinyl-2)-aminoalkyl)-1 piperidines, leur preparation et leur application en therapeutique
EP0350403A1 (de) (Aza)Naphtalensultam-Derivate, Verfahren zu deren Herstellung und Arzneimittel, die sie enthalten
EP0125195B1 (de) 4'-Flavonkarbonsäuren, Verfahren zu deren Herstellung und ihre therapeutische Verwendung
EP0319412B1 (de) 2-Piperazinyl-2-oxo-äthylensubstituierte Flavonoid-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
US4134991A (en) Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid
EP0479631A1 (de) Spiro[4,5]decanderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
BE1009852A3 (fr) Derives 1-[2(vinyl-substitues)]-3-4-dihydro-5h-2,3-benzodiazepine.
US4025649A (en) Acetic acid derivatives having pharmacological activity and compositions containing the same
EP0004494A1 (de) 1,3-Dihydro-3-(1-(2-(2,3-dihydro-1,4-benzodioxin-2-yl)2-hydroxy-äthyl)piperidin-4-yl)2H-indol-2-on Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zubereitungen
EP0301936B1 (de) Piperidin-Derivate, deren Herstellung und deren Verwendung als Heilmittel
EP0074903A2 (de) 2-Amino-1,2,3,4-tetrahydronaphthalen-Derivate, ihre Herstellung und ihre therapeutische Verwendung
FR2610932A1 (fr) Nouvel acide piperazinecarboxylique, sa preparation et son utilisation comme medicament
JPS61286359A (ja) Ｎ−〔〔５−（トリフルオロメチル）−６−メトキシ−１−ナフタレニル〕チオキソメチルまたはカルボニル〕−ｎ−メチルグリシンアミド
FR2508457A1 (fr) Pyrrolo(2,1-b)quinazolines et pyrido(2,1-b)quinazolines substituees, leur preparation et leurs utilisations therapeutiques
EP0002401B1 (de) Naphtalen-Derivate, Verfahren zu deren Herstellung und deren Verwendung in der Therapeutik
EP0427605B1 (de) Morpholinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen

Legal Events

Date Code Title Description
ST Notification of lapse